BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy.

15 In a recent pilot randomised controlled trial (RCT) which was terminated prematurely due to technical reasons, administration of benfotiamine over 6 months (600 mg/day for 3 months, followed by 300 mg/day until the study end) resulted in a reduction of neuropathic symptoms assessed by the Michigan Neuropathy Screening Instrument (MNSI) questionnaire, while changes in neuropathic deficits (MNSI physical examination), quality of life and pain did not reach statistical significance. 4 16 In people with diabetes as well as in tobacco smoking individuals, benfotiamine was shown to improve endothelial function. 17 18 The safety profile of benfotiamine is excellent. 4 Milgamma mono 300 (containing 300 mg benfotiamine) was approved in 2005 for the treatment or prophylaxis of clinically manifest vitamin B1 deficiency if a dietary supplementation is not effective 19 and for the treatment of neuropathies and cardiovascular disorders caused by vitamin B 1 deficiency.

also in 111,027 other papers